Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 20 of 730 for:    Area Under Curve AND Bioavailability

A Three-Period Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01710995
Recruitment Status : Completed
First Posted : October 19, 2012
Last Update Posted : October 19, 2012
Sponsor:
Information provided by (Responsible Party):
Norgine

Brief Summary:
The purpose of this study is to assess the effectiveness of Zegerid 20mg capsules and powder and Losec 20mg capsules in healthy volunteers under fasting conditions.

Condition or disease Intervention/treatment Phase
Acid Reflux Gastro Oesophageal Reflux Disease Drug: Zegerid Drug: Losec Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Randomised, Three-Period, Single Dose, Open-Label, Crossover Study to Investigate the Relative Bioavailability and Pharmacodynamic Profiles of a Zegerid 20mg Capsule, Zegerid 20mg Powder for Oral Suspension and Losec 20mg Capsule in Healthy Adult Volunteers Under Fasting Conditions
Study Start Date : October 2010
Actual Primary Completion Date : November 2010
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Zegerid 20mg capsule
Zegerid 20mg capsule (20mg omeprazole and 1100mg sodium carbonate
Drug: Zegerid
Active Comparator: Zegerid 20mg powder for oral suspension
Zegerid 20mg powder for oral suspension (20mg omeprazole and 1680mg sodium bicarbonate)
Drug: Zegerid
Active Comparator: Losec 20mg capsule
Losec 20mg capsule (20mg omeprazole)
Drug: Losec



Primary Outcome Measures :
  1. Bioavailability - Area under Curve of pH at 2 hours [ Time Frame: 2 hours ]
    To assess the relative bioavailability of two immediate release formulations of omeprazole/sodium carbonate (Zegerid 20mg capsule and Zegerid 20mg powder for oral suspension)

  2. Pharmacodynamics - Area under Curve of pH at 2 hours [ Time Frame: 2 hours ]
    To assess the relative pharmacodynamic profiles of two immediate release formulations of omeprazole/sodium bicarbonate (Zegerid® 20mg capsule and Zegerid® 20mg powder for oral suspension).


Secondary Outcome Measures :
  1. Safety and tolerability of study formulations using measurements of Cmax, tmax and t1/2 [ Time Frame: pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose ]
    To assess the safety and tolerability of these three formulations after single dose oral administration. To include measurements of Cmax, tmax and t1/2

  2. Bioavailability - measurement of pH over time [ Time Frame: 0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours ]
    To assess the relative bioavailability of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg capsule) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state. AUC of pH and % of time for pH to raise above 4 (0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours)

  3. Bioavailability - measurement of pH over time [ Time Frame: 0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours ]
    To assess the relative bioavailability of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg powder for oral suspension) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state. AUC of pH and % of time for pH to raise above 4 (0.5, 1, 1.5, 3, 4, 8, 12, 16 and 24 hours)

  4. Pharmacodynamic Measurements of Cmax, Tmax and t1/2 [ Time Frame: Pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose ]
    To assess the relative pharmacodynamic profiles of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg capsule) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state.

  5. Pharmacodynamic measurements of Cmax, Tmax and t1/2 [ Time Frame: Pre-dose on day 1, and at 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 10, 12, 16 and 24 hours post-dose ]
    To assess the relative pharmacodynamic profiles of an immediate release formulation of omeprazole/sodium bicarbonate (Zegerid 20mg powder for oral suspension) and a delayed-release omeprazole capsule (Losec 20mg) after single dose oral administration in a fasted state



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy adult male or female volunteers aged 18 - 45 years.
  • Non-smokers from three months before receiving the first dose and for the duration of the study, confirmed by negative urinary cotinine test at screening and check-in.
  • Body mass index (BMI) ≥ 18.0 and ≤ 27.9 kg/m2.
  • Able to voluntarily provide written informed consent to participate in the study.
  • Must understand the purposes and risks of the study and agree to follow the restrictions and schedule of procedures as defined in the protocol.
  • Able and willing to have a nasogastric tube/probe inserted.
  • Females must be post-menopausal (for at least one year and confirmed by serum FSH at screening), surgically sterile, practicing true sexual abstinence or using an acceptable form of effective contraception throughout the study from the following list: contraceptive implants, injectables, oral contraceptives, intrauterine system (IUS), some intrauterine devices (IUDs), vasectomised partner or barrier method (condom or occlusive cap) with spermicidal foam/gel/film/cream/suppository.
  • Hormonal and IUD methods of contraception must be established for a period of three months prior to dosing and cannot be changed or altered during the study.
  • Females of childbearing potential must have a negative pregnancy test at screening and check-in.
  • Must be willing to consent to have data entered into The Over Volunteering Prevention System (TOPS).
  • The volunteer's primary care physician must confirm that there is nothing in their medical history that would preclude their enrolment into this clinical study.

Exclusion Criteria:

  • Positive for HIV, hepatitis B or hepatitis C.
  • History or presence of significant cardiovascular, pulmonary, hepatic, renal, haematological, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease as determined by the Investigator.
  • History of gastric or duodenal ulcer.
  • History of hiatus hernia.
  • Significant history of reflux symptoms on clinical judgement.
  • Diagnosis of conditions likely to result in a hypersecretory gastric acid state e.g. Zollinger-Ellison Syndrome.
  • Positive serology test result for H. pylori at screening.
  • Clinically significant deviated nasal septum or other nasopharyngeal obstruction, or inability to tolerate or site a nasogastric tube at screening.
  • Hypersensitivity or any other contraindication to Zegerid® or Losec®.
  • History or presence of any clinically significant drug allergy.
  • Female subjects who are pregnant or lactating.
  • Laboratory values at screening which are deemed to be clinically significant as determined by the Investigator.
  • Any clinically relevant history of drug or alcohol abuse.
  • Volunteers who, in the opinion of the Investigator, are unsuitable for participation in the study.
  • Participation in a clinical drug study during the 90 days preceding the initial dose of study medication.
  • Any significant illness during the screening period preceding the initial dose of study medication.
  • Donation of blood or blood products within 90 days prior to study drug administration, or at any time during the study, except as required by this protocol.
  • Consumption of alcoholic beverages or xanthine-containing products within 24 hours before confinement or during study confinement.
  • Consumption of cruciferous vegetables or chargrilled foods within 48 hours before confinement or during study confinement.
  • Consumption of grapefruit or grapefruit juice from seven days before confinement and until the end of the study.
  • Use of any prescription or over-the-counter medication (including vitamins, herbal and mineral supplements) within 30 days before study drug administration, or any general anaesthetic during the three months before study drug administration, and until the end of the study, with the exception of Investigator-approved hormonal contraceptives, HRT and occasional paracetamol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01710995


Locations
Layout table for location information
United Kingdom
Bio-Kinetic Europe Limited, 14 Great Victoria Street, Belfast BT2 7BA
Belfast, United Kingdom, BT2 7BA
Sponsors and Collaborators
Norgine
Investigators
Layout table for investigator information
Principal Investigator: Jerome Hanna, MB BCH MRCS Bio-Kinetic Europe, Ltd.

Layout table for additonal information
Responsible Party: Norgine
ClinicalTrials.gov Identifier: NCT01710995     History of Changes
Other Study ID Numbers: ZEG-02/2010 (BE)
First Posted: October 19, 2012    Key Record Dates
Last Update Posted: October 19, 2012
Last Verified: October 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Gastroesophageal Reflux
Esophageal Motility Disorders
Deglutition Disorders
Esophageal Diseases
Gastrointestinal Diseases
Digestive System Diseases
Omeprazole
Omeprazole, sodium bicarbonate drug combination
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Ulcer Agents
Gastrointestinal Agents